BNF for Children (BNFC) 2018-2019

▶Idelalisibis predicted to increase the exposure toguanfacine.
Adjustguanfacinedose,p. 231.oStudy
▶Idelalisibis predicted to very markedly increase the exposure
toibrutinib. Avoid potent inhibitors of CYP3A4 or adjust
ibrutinibdose.rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure toimatinib.
oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the risk of toxicity when
given withirinotecan. Avoid.oStudy→Also seeTABLE 15
p. 850
▶Idelalisibis predicted to increase the exposure toivabradine.
Avoid.rStudy
▶Idelalisibis predicted to increase the exposure toivacaftor.
Adjustivacaftorp. 186orlumacaftor with ivacaftorp. 187dose
with potent inhibitors of CYP3A4.rStudy
▶Idelalisibis predicted to increase the exposure tolapatinib.
Avoid.oStudy
▶Idelalisibis predicted to markedly increase the exposure to
lomitapide. Avoid.rStudy
▶Idelalisibis predicted to increase the exposure tolurasidone.
Avoid.rStudy
▶Idelalisibis predicted to increase the exposure tomacitentan.
oStudy
▶Idelalisibmarkedly increases the exposure tomaraviroc.
Adjust dose.rTheoretical
▶Idelalisibis predicted to markedly to very markedly increase
the exposure tomidazolam. Avoid or adjust dose.rStudy
▶Idelalisibis predicted to very markedly increase the exposure
tomidostaurin. Avoid or monitor for toxicity.rStudy
▶Idelalisibis predicted to increase the exposure tomirabegron.
Adjustmirabegrondose in hepatic and renal impairment.
oStudy
▶Idelalisibis predicted to increase the exposure tomirtazapine.
oStudy
▶Mitotaneis predicted to decrease the exposure toidelalisib.
Avoid.rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure tomodafinil.
nTheoretical
▶Idelalisibis predicted to increase the exposure tomonoclonal
antibodies(trastuzumab emtansine). Avoid.rTheoretical→
Also seeTABLE 15p. 850
▶Idelalisibis predicted to markedly increase the exposure to
naloxegol. Avoid.rStudy
▶Idelalisibis predicted to increase the exposure tonetupitant.
oStudy
▶Nevirapineis predicted to decrease the exposure toidelalisib.
Avoid.oTheoretical
▶Idelalisibis predicted to moderately increase the exposure to
nilotinib. Avoid.rStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure tonitisinone.
Adjust dose.oTheoretical
▶Idelalisibis predicted to increase the exposure toolaparib.
Avoid potent inhibitors of CYP3A4 or adjustolaparibdose.
oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure toopioids
(alfentanil, buprenorphine, fentanyl, oxycodone, sufentanil).
Monitor and adjust dose.rStudy
▶Idelalisibis predicted to increase the exposure toopioids
(methadone).rTheoretical
▶Idelalisibis predicted to increase the exposure tooxybutynin.
nStudy
▶Idelalisibis predicted to increase the exposure topalbociclib.
Avoid or adjustpalbociclibdose.rStudy
▶Idelalisibis predicted to increase the exposure to
panobinostat. Adjustpanobinostatdose; in hepatic
impairment avoid.oStudy→Also seeTABLE 15p. 850
▶Idelalisibis predicted to increase the exposure toparitaprevir
(with ritonavir and ombitasvir). Avoid.rTheoretical
▶Idelalisibis predicted to increase the exposure topazopanib.
Avoid or adjustpazopanibdose.oStudy→Also see
TABLE 15p. 850
▶Idelalisibis predicted to increase the exposure to
phosphodiesterase type-5 inhibitors(avanafil, vardenafil). Avoid.
rStudy

▶Idelalisibis predicted to increase the exposure to

phosphodiesterase type-5 inhibitors(sildenafil). Avoid potent

inhibitors of CYP3A4 or adjustsildenafildose,p. 120.r

Study

▶Idelalisibis predicted to increase the exposure to

phosphodiesterase type-5 inhibitors(tadalafil). Use with caution

or avoid.rStudy

▶Idelalisibis predicted to increase the exposure topimozide.

Avoid.rStudy

▶Idelalisibis predicted to slightly increase the exposure to

ponatinib. Monitor and adjustponatinibdose.oStudy

▶Idelalisibis predicted to moderately increase the exposure to

praziquantel.nStudy

▶Idelalisibis predicted to increase the exposure toquetiapine.

Avoid.rStudy

▶Idelalisibis predicted to increase the exposure toranolazine.

Avoid.rStudy

▶Idelalisibis predicted to increase the exposure toreboxetine.

Avoid.oStudy

▶Idelalisibis predicted to increase the exposure toregorafenib.

Avoid.oStudy→Also seeTABLE 15p. 850

▶Idelalisibis predicted to increase the exposure torepaglinide.

oStudy

▶Idelalisibis predicted to increase the exposure toretinoids

(alitretinoin). Adjustalitretinoindose.oTheoretical

▶Idelalisibis predicted to increase the exposure toribociclib.

Avoid or adjustribociclibdose.oStudy

▶Rifampicinis predicted to decrease the exposure toidelalisib.

Avoid.rStudy

▶Idelalisibis predicted to increase the exposure torisperidone.

Adjust dose.oStudy

▶Idelalisibis predicted to increase the exposure toruxolitinib.

Adjust dose and monitor side effects.oStudy→Also see

TABLE 15p. 850

▶Idelalisibis predicted to increase the exposure tosaxagliptin.

oStudy

▶Idelalisibis predicted to increase the exposure tosimeprevir.

Avoid.rStudy

▶Idelalisibis predicted to increase the concentration of

sirolimus. Avoid.rStudy

▶Idelalisibis predicted to increase the exposure tosolifenacin.

Adjustsolifenacinortamsulosin with solifenacin dose; avoid

in hepatic and renal impairment.rStudy

▶Idelalisibis predicted to moderately increase the exposure to

SSRIs(dapoxetine). Avoid potent inhibitors of CYP3A4 or

adjustdapoxetinedose.rStudy

▶St John’sWortis predicted to decrease the exposure to

idelalisib. Avoid.oTheoretical

▶Idelalisibis predicted to increase the exposure tostatins

(atorvastatin). Avoid or adjust dose and monitor

rhabdomyolysis.rStudy

▶Idelalisibis predicted to increase the exposure tostatins

(simvastatin). Avoid.rStudy

▶Idelalisibis predicted to slightly increase the exposure to

sunitinib. Avoid or adjustsunitinibdose.oStudy→Also

seeTABLE 15p. 850

▶Idelalisibis predicted to increase the concentration of

tacrolimus. Monitor and adjust dose.rStudy

▶Idelalisibis predicted to increase the exposure totaxanes

(cabazitaxel). Avoid.rStudy→Also seeTABLE 15p. 850

▶Idelalisibis predicted to moderately increase the exposure to

taxanes(docetaxel). Avoid or adjust dose.rStudy→Also

seeTABLE 15p. 850

▶Idelalisibis predicted to increase the exposure totaxanes

(paclitaxel).rTheoretical→Also seeTABLE 15p. 850

▶Idelalisibis predicted to increase the concentration of

temsirolimus. Avoid.rTheoretical→Also seeTABLE 15p. 850

▶Idelalisibis predicted to markedly increase the exposure to

ticagrelor. Avoid.rStudy

▶Idelalisibis predicted to increase the exposure totofacitinib.

Adjusttofacitinibdose.oStudy

▶Idelalisibis predicted to increase the exposure totolterodine.

Avoid.rStudy

▶Idelalisibis predicted to increase the exposure totolvaptan.

Adjust dose.rStudy

BNFC 2018 – 2019 Idelalisib—Idelalisib 935

Interactions

|Appendix 1

A1